Updated on 2022/03/24

写真a

 
SHIMOKATA Tomoya
 
Organization
Nagoya University Hospital Clinical Oncology and Chemotherapy Lecturer of hospital
Title
Lecturer of hospital
Contact information
メールアドレス

Degree 1

  1. 博士(医学) ( 2010.11   名古屋大学 ) 

Research Interests 1

  1. Clinical Oncology

Research Areas 1

  1. Others / Others  / Clinical Oncology

Current Research Project and SDGs 1

  1. がん薬物療法における臨床薬理

Education 2

  1. Nagoya University   Graduate School, Division of Medical Sciences

    - 2010.3

      More details

    Country: Japan

  2. Nagoya University   Faculty of Medicine

    - 2000.3

      More details

    Country: Japan

Professional Memberships 7

  1. 日本内科学会

  2. 日本呼吸器学会

  3. 日本癌学会

  4. 日本呼吸器内視鏡学会

  5. 日本肺癌学会

  6. 日本臨床薬理学会

  7. 日本臨床腫瘍学会

▼display all

 

Papers 22

  1. Drug-induced thrombocytopenia associated with trastuzumab in a patient with HER2-positive recurrent gastric cancer

    Takano Yuko, Furune Satoshi, Miyai Yuki, Morita Sachi, Inoue Megumi, Shimokata Tomoya, Sugishita Mihoko, Mitsuma Ayako, Maeda Osamu, Ando Yuichi

    INTERNATIONAL CANCER CONFERENCE JOURNAL   Vol. 11 ( 1 ) page: 67 - 70   2022.1

     More details

  2. Vitiligo and tumor response in a patient with amelanotic melanoma undergoing nivolumab treatment (Oct, 10.1007/s13691-021-00515-w, 2021)

    Furune Satoshi, Kondo Chiaki, Takano Yuko, Shimokata Tomoya, Sugishita Mihoko, Mitsuma Ayako, Maeda Osamu, Ando Yuichi

    INTERNATIONAL CANCER CONFERENCE JOURNAL   Vol. 11 ( 1 ) page: 49 - 49   2022.1

     More details

  3. Increased risk of thyroid dysfunction by PD-1 and CTLA-4 blockade in patients without thyroid autoantibodies at baseline.

    Iwama S, Kobayashi T, Yasuda Y, Okuji T, Ito M, Ando M, Zhou X, Yamagami A, Onoue T, Kawaguchi Y, Miyata T, Sugiyama M, Takagi H, Hagiwara D, Suga H, Banno R, Hase T, Morise M, Wakahara K, Yokota K, Kato M, Nishio N, Tanaka C, Miyata K, Ogura A, Ito T, Sawada T, Shimokata T, Niimi K, Ohka F, Ishigami M, Gotoh M, Hashimoto N, Saito R, Kiyoi H, Kajiyama H, Ando Y, Hibi H, Sone M, Akiyama M, Kodera Y, Arima H

    The Journal of clinical endocrinology and metabolism     2021.11

     More details

    Language:English  

    DOI: 10.1210/clinem/dgab829

    PubMed

  4. Vitiligo and tumor response in a patient with amelanotic melanoma undergoing nivolumab treatment

    Furune Satoshi, Kondo Chiaki, Takano Yuko, Shimokata Tomoya, Sugishita Mihoko, Mitsuma Ayako, Maeda Osamu, Ando Yuichi

    INTERNATIONAL CANCER CONFERENCE JOURNAL     2021.10

     More details

  5. Prognostic impact of immune-related adverse events on patients with and without cardiovascular disease: a retrospective review

    Kazama Shingo, Morimoto Ryota, Kimura Yuki, Shibata Naoki, Ozaki Reina, Araki Takashi, Mizutani Takashi, Oishi Hideo, Arao Yoshihito, Kuwayama Tasuku, Hiraiwa Hiroaki, Kondo Toru, Furusawa Kenji, Shimokata Tomoya, Okumura Takahiro, Bando Yasuko K., Ando Yuichi, Murohara Toyoaki

    CARDIO-ONCOLOGY   Vol. 7 ( 1 ) page: 26   2021.7

     More details

  6. Guidelines for clinical evaluation of anti-cancer drugs

    Minami Hironobu, Kiyota Naomi, Kimbara Shiro, Ando Yuichi, Shimokata Tomoya, Ohtsu Atsushi, Fuse Nozomu, Kuboki Yasutoshi, Shimizu Toshio, Yamamoto Noboru, Nishio Kazuto, Kawakami Yutaka, Nihira Shin-ichi, Sase Kazuhiro, Nonaka Takahiro, Takahashi Hideaki, Komori Yukiko, Kiyohara Koshin

    CANCER SCIENCE   Vol. 112 ( 7 ) page: 2563 - 2577   2021.7

     More details

  7. A case of recurrent gastric cancer with drug-induced immune thrombocytopenia caused by trastuzumab

    Takano Yuko, Furune Satoshi, Morita Sachi, Inoue Megumi, Shimokata Tomoya, Sugishita Mihoko, Mitsuma Ayako, Osamu Maeda, Ando Yuichi

    ANNALS OF ONCOLOGY   Vol. 32   page: S354 - S354   2021.7

     More details

  8. Phase I study of the antiprogrammed cell death-1 Ab spartalizumab (PDR001) in Japanese patients with advanced malignancies

    Minami Hironobu, Doi Toshihiko, Toyoda Masanori, Imamura Yoshinori, Kiyota Naomi, Mitsuma Ayako, Shimokata Tomoya, Naito Yoichi, Matsubara Nobuaki, Tajima Takeshi, Tokushige Kota, Ishihara Kae, Cameron Scott, Ando Yuichi

    CANCER SCIENCE   Vol. 112 ( 2 ) page: 725 - 733   2021.2

     More details

  9. Chemotherapy for biliary tract cancer: real-world experience in a single institute

    Maeda Osamu, Ebata Tomoki, Shimokata Tomoya, Matsuoka Ayumu, Inada-Inoue Megumi, Morita Sachi, Takano Yuko, Urakawa Hiroshi, Miyai Yuki, Sugishita Mihoko, Mitsuma Ayako, Ando Masahiko, Mizuno Takashi, Nagino Masato, Ando Yuichi

    NAGOYA JOURNAL OF MEDICAL SCIENCE   Vol. 82 ( 4 ) page: 725 - 733   2020.11

     More details

  10. Solitary fibrous tumor/hemangiopericytoma treated with temozolomide plus bevacizumab: a report of four cases and literature review

    Maeda Osamu, Ohka Fumiharu, Maesawa Satoshi, Matsuoka Ayumu, Shimokata Tomoya, Mitsuma Ayako, Urakawa Hiroshi, Nakamura Shota, Shimoyamas Yoshic, Nakaguro Masato S., Wakabayashi Toshihiko, Ando Yuichi

    NAGOYA JOURNAL OF MEDICAL SCIENCE   Vol. 82 ( 4 ) page: 631 - 644   2020.11

     More details

  11. 5-FU, Irinotecan, Nab-Paclitaxel in Gastrointestinal Cancers-Letter

    Maeda Osamu, Shimokata Tomoya, Ando Yuichi

    CLINICAL CANCER RESEARCH   Vol. 26 ( 14 ) page: 3889 - 3889   2020.7

     More details

  12. Clinical value of serum bone resorption markers for predicting clinical outcomes after use of bone modifying agents in metastatic bone tumors: A prospective cohort study

    Urakawa Hiroshi, Ando Yuichi, Hase Tetsunari, Kikumori Toyone, Arai Eisuke, Maeda Osamu, Mitsuma Ayako, Sugishita Mihoko, Shimokata Tomoya, Ikuta Kunihiro, Ishiguro Naoki, Nishida Yoshihiro

    INTERNATIONAL JOURNAL OF CANCER   Vol. 146 ( 12 ) page: 3504 - 3515   2020.6

     More details

  13. Detection of bacteria in blood circulation in patients receiving cancer chemotherapy.

    Ota A, Morita S, Matsuoka A, Shimokata T, Maeda O, Mitsuma A, Yagi T, Asahara T, Ando Y

    International journal of clinical oncology   Vol. 25 ( 1 ) page: 210 - 215   2020.1

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s10147-019-01521-y

    Web of Science

    PubMed

  14. Correlation Between the Metabolic Conversion of a Capecitabine Metabolite, 5 '-Deoxy-5-fluorocytidine, and Creatinine Clearance

    Inaishi Takahiro, Fujita Ken-Ichi, Matsumoto Natsumi, Shimokata Tomoya, Maeda Osamu, Kikumori Toyone, Hattori Norifumi, Nakayama Goro, Ando Yuichi

    IN VIVO   Vol. 34 ( 6 ) page: 3539 - 3544   2020

     More details

  15. Phase 1 study of olaratumab plus doxorubicin in Japanese patients with advanced soft-tissue sarcoma

    Yonemori Kan, Kodaira Makoto, Satoh Taroh, Kudo Toshihiro, Takahashi Shunji, Nakano Kenji, Ando Yuichi, Shimokata Tomoya, Mori Joji, Inoue Koichi, Oakley Gerard J., Sakaguchi Sachi, Tamura Kenji

    CANCER SCIENCE   Vol. 109 ( 12 ) page: 3962 - 3970   2018.12

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/cas.13846

    Web of Science

    PubMed

  16. Reporting harms more transparently in trials of cancer drugs

    Gyawali Bishal, Shimokata Tomoya, Honda Kazunori, Ando Yuichi

    BMJ-BRITISH MEDICAL JOURNAL   Vol. 363   page: k4383   2018.11

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    DOI: 10.1136/bmj.k4383

    Web of Science

    PubMed

  17. Outpatient chemotherapy for patients with unresectable or metastatic bone sarcomas

    Urakawa Hiroshi, Nishida Yoshihiro, Mitsuma Ayako, Maeda Osamu, Sugishita Mihoko, Shimokata Tomoya, Mizutani Takeshi, Arai Eisuke, Ikuta Kunihiro, Hamada Shunsuke, Ota Takehiro, Ishiguro Naoki, Ando Yuichi

    ANNALS OF ONCOLOGY   Vol. 29   page: .   2018.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Web of Science

  18. Feasibility of dose-dense epirubicin and cyclophosphamide with subcutaneous pegfilgrastim 3.6 mg support: a single-center prospective study in Japan

    Morita Sachi, Kikumori Toyone, Tsunoda Nobuyuki, Inaishi Takahiro, Adachi Yayoi, Ota Akiko, Shibata Masahiro, Matsuoka Ayumu, Nakanishi Kenichi, Takeuchi Dai, Mizutani Takefumi, Shimokata Tomoya, Hayashi Hironori, Maeda Osamu, Ando Yuichi

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   Vol. 23 ( 1 ) page: 195 - 200   2018.2

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s10147-017-1177-z

    Web of Science

    PubMed

  19. Real-world experience with FOLFIRINOX and gemcitabine plus nab-paclitaxel in the treatment of pancreatic cancer in Japan

    Maeda O., Yokoyama Y., Yamaguchi J., Ota A., Matsuoka A., Morita S., Inoue M., Mizutani T., Shimokata T., Urakawa H., Mitsuma A., Nagino M., Ando Y.

    ANNALS OF ONCOLOGY   Vol. 28   page: 69-69   2017.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Web of Science

  20. Gemcitabine plus cisplatin and S-1 for biliary tract cancer: a single institute analysis

    Maeda Osamu, Shimokata Tomoya, Mizutani Takefumi, Inoue Megumi, Matsuoka Ayumu, Ota Akiko, Mizuno Takashi, Ebata Tomoki, Nagino Masato, Ando Yuichi

    ANNALS OF ONCOLOGY   Vol. 28   page: 50-50   2017.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Web of Science

  21. Correlation and differences in Effect sizes between Progression Free Survival (PFS) and Overall Survival (OS) among PD-1 inhibitors

    Gyawali B., Shimokata T., Ando Y.

    ANNALS OF ONCOLOGY   Vol. 28   page: .   2017.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Web of Science

  22. Risk of serious adverse events and fatal adverse events with sorafenib in patients with solid cancer: a meta-analysis of phase 3 randomized controlled trials. Reviewed

    Bishal Gyawali, Tomoya Shimokata, Masahiko Ando, Kazunori Honda, Yuichi Ando

    Annals of Oncology   Vol. 28 ( 2 ) page: 246-253   2016.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: doi:10.1093/annonc/mdw549

▼display all

MISC 8

  1. Chemotherapy in locally advanced head and neck squamous cell carcinoma Reviewed

    Gyawali Bishal, Shimokata Tomoya, Honda Kazunori, Ando Yuichi

    CANCER TREATMENT REVIEWS   Vol. 44   page: 10-16   2016.3

     More details

  2. Opioid-induced constipation. Reviewed

    Gyawali B, Hayashi N, Tsukuura H, Honda K, Shimokata T, Ando Y

    Scandinavian journal of gastroenterology   Vol. 50 ( 11 ) page: 1331-8   2015

     More details

    Language:English  

    DOI: 10.3109/00365521.2015.1054423

    PubMed

  3. Association between severe toxicity of nilotinib and UGT1A1 polymorphisms in Japanese patients with chronic myelogenous leukemia. Reviewed

    Shibata T, Minami Y, Mitsuma A, Morita S, Inada-Inoue M, Oguri T, Shimokata T, Sugishita M, Naoe T, Ando Y

    International journal of clinical oncology   Vol. 19 ( 2 ) page: 391-6   2014.4

     More details

    Language:English  

    DOI: 10.1007/s10147-013-0562-5

    PubMed

  4. Carboplatin dosing for adult Japanese patients. Reviewed

    Ando Y, Shimokata T, Yasuda Y, Hasegawa Y

    Nagoya journal of medical science   Vol. 76 ( 1-2 ) page: 1-9   2014.2

     More details

    Language:English  

    PubMed

  5. Genetic polymorphisms associated with oxaliplatin-induced peripheral neurotoxicity in Japanese patients with colorectal cancer. Reviewed

    Oguri T, Mitsuma A, Inada-Inoue M, Morita S, Shibata T, Shimokata T, Sugishita M, Nakayama G, Uehara K, Hasegawa Y, Ando Y

    International journal of clinical pharmacology and therapeutics   Vol. 51 ( 6 ) page: 475-81   2013.6

     More details

    Language:English  

    DOI: 10.5414/CP201851

    PubMed

  6. Association between bevacizumab-related hypertension and vascular endothelial growth factor (VEGF) gene polymorphisms in Japanese patients with metastatic colorectal cancer. Reviewed

    Morita S, Uehara K, Nakayama G, Shibata T, Oguri T, Inada-Inoue M, Shimokata T, Sugishita M, Mitsuma A, Ando Y

    Cancer chemotherapy and pharmacology   Vol. 71 ( 2 ) page: 405-11   2013.2

     More details

    Language:English  

    DOI: 10.1007/s00280-012-2028-2

    PubMed

  7. Prospective evaluation of pharmacokinetically guided dosing of carboplatin in Japanese patients with cancer. Reviewed

    Shimokata T, Ando Y, Yasuda Y, Hamada A, Kawada K, Saito H, Matsuo S, Kondo M, Imaizumi K, Hasegawa Y

    Cancer science   Vol. 101 ( 12 ) page: 2601-5   2010.12

     More details

    Language:English  

    DOI: 10.1111/j.1349-7006.2010.01729.x

    PubMed

  8. Pharmacokinetic analysis of carboplatin in patients with cancer who are undergoing hemodialysis. Reviewed

    Oguri T, Shimokata T, Inada M, Ito I, Ando Y, Sasaki Y, Hasegawa Y

    Cancer chemotherapy and pharmacology   Vol. 66 ( 4 ) page: 813-7   2010.9

     More details

    Language:English  

    DOI: 10.1007/s00280-010-1366-1

    PubMed

▼display all

KAKENHI (Grants-in-Aid for Scientific Research) 5

  1. がん薬物療法における抗がん薬曝露に対する科学的エビデンスの創出

    Grant number:19K07083  2019.4 - 2023.3

    科学研究費助成事業  基盤研究(C)

    満間 綾子, 安藤 雄一, 下方 智也

      More details

    Authorship:Coinvestigator(s) 

    新規抗がん薬の開発により、外来化学療法で取り扱う抗がん薬レジメンは増加する一方である。外来化学療法室の利用患者は年々増加し、多様なニーズに応えるがん薬物療法に習熟した医療者の関わりが重要となっている。がん薬物療法を専門とする医療者の育成、拡充にあたっては、専門的な教育・訓練とともに抗がん薬を扱う現場における医療者の安全、職場環境の整備も提唱されている。曝露防止のための機器開発が進む中で過去の報告は現状と乖離しており、医療者がコストと時間をかけてどこまで曝露対策を行うかの科学的実証は未確立である。本研究では、抗がん薬曝露の実態を経年的・経時的に調査し現状に即したエビデンスを創出する。
    本研究では、がん薬物療法における抗がん薬曝露の実態を調査し、繰り返しモニタリングを行うことで、国内での閾値の設定や予防の根拠となるエビデンスを創出することを目的としている。当院外来化学療法室では、院内すべての点滴抗がん薬の外来投与を専任の医療者が担当している。年間10000件以上の実施にあたり、職業性曝露のモニタリングとして環境モニタリングと生物学的モニタリングの経年的実施を行う。
    <環境モニタリング>
    当院外来化学療法室での環境モニタリングを行うにあたり、モニタリングの手法、場所を絞り込んだ後に、抗がん薬曝露予防を目的とした機器導入、マニュアルの改訂・整備の現状を把握できている。閉鎖式薬物移送システム(closed system drug transfer device: CSTD) は、当院において抗がん薬のミキシングすべてには使用していない。揮発性抗がん薬にのみCSTDを使用している。これまでのモニタリング結果では既報に比べて汚染の度合いを示す測定値は低く、現状での手法により経時的にモニタリングを進めている。
    <生物学的モニタリング>
    外来化学療法室で実施する膀胱内注入後の抗がん薬曝露について、同意を得た患者および医療者の排尿より生物学的モニタリングを行う。ドキソルビシンの投与が予定されており、投与量、排尿回数など臨床薬理学的解析を加えて経時的変化を観察する予定であったが、治療対象者が乏しい状況が続いている。がん関連学会での情報収集を継続した。侵襲の程度が少ない新たな手法(唾液検体からの検出)では検体量の採取に時間がかかることが判明した。
    環境モニタリングは順調に推移している。昨年同様、生物学的モニタリングは対象患者が乏しい状況があった。新規薬剤の導入やCOVID-19により高齢患者など地元での治療ニーズが高い影響を考える。
    生物学的モニタリングの対象となる泌尿器疾患の患者が減少している。新規薬剤の導入やCOVID-19による影響が考えられ、今後の増加は難しい状況である。研究代表者および研究分担者との討議を定期的に行っており、引き続き現状での研究の推進に努める。

  2. Mechanism of diarrhea/enteritis caused by anticancer drugs and development of new treatment

    Grant number:17K08950  2017.4 - 2020.3

    Ando Yuichi

      More details

    Authorship:Coinvestigator(s) 

    By focusing on bacterial-translocation, phenomenon in which human intestinal bacteria migrate into circulating blood in human body via intestinal wall, using highly-sensitive detection assay for viable bacteria, I investigated whether bacteria in the blood would be associated with the occurrence of adverse effects of cancer chemotherapy. The results revealed that patients with cancer were always prone to bacterial-translocations regardless of the administration of anticancer drugs, suggesting that bacterial-translocation would be the cause of febrile neutropenia, infection, and diarrhea/enteritis, which are caused by cancer chemotherapy.

  3. Screening and prevention of vascular events for cancer patients, and investigation of the mechanisms.

    Grant number:16K08906  2016.4 - 2020.3

    Mitsuma Ayako

      More details

    Authorship:Coinvestigator(s) 

    Some newly developed cancer chemotherapy drugs cause hemorrhage or thrombosis as adverse event through inhibition of angiogenesis. Prolonged survival and aging of cancer patients lead to increase of patients using anticoagulats to prevent cardiovascular disease. In this study we evaluated risk of cancer associated thrombosis receiving outpatient treatment, including drug interactions. We compared our data with predictive model proposed in foreign studies. We found no difference in outcome of treatment with specific anticoagulants. Effects of cancer chemotherapy and condition of patients influenced clinical course of thrombosis.

  4. Elucidation of sarcopenia mechanism in the cancer cachexia

    Grant number:15K08906  2015.4 - 2019.3

    Shimokata Tomoya

      More details

    Authorship:Principal investigator 

    Grant amount:\4810000 ( Direct Cost: \3700000 、 Indirect Cost:\1110000 )

    We evaluated the body composition, muscle mass and adipose tissue, in patients who received cancer pharmacotherapy to test a hypothesis that the adipose tissue plays an important role in the process to cancer cachexia. We analyzed the change of the body composition in patients who received monotherapy of the mTOR inhibitor more than six months retrospectively. The muscle mass significantly decreased, but there were no significant changes in the adipose tissue quantity. Also, we performed a cohort study to evaluate a body composition change and a metabolic rate as subjects in the patients prospectively. We accumulate 28 cases and final analysis is in progress.

  5. Clinical significance of sarcopenia in cancer chemotherapy

    Grant number:26460626  2014.4 - 2018.3

    Ando Yuichi

      More details

    Authorship:Coinvestigator(s) 

    The aim of this study is investigated sarcopenia in cancer patients who underwent cancer chemotherapy in order to test the hypothesis that those patients with sarcopenia are more likely to experience severe toxicity and then poorly tolerate the treatment. First, we retrospectively analyzed the change of skeletal muscle mass in patients treated with an mTOR inhibitor and reported that the muscle mass was significantly reduced by treatment. Subsequently, an observational study was conducted to prospectively evaluate sarcopenia up to for 6 months in cancer patients who received a kinase inhibitor containing mTOR inhibitor. Of the 28 patients enrolled, 17 and 7 patients completed the 6-month and 3-month follow-ups, respectively. Final analysis of the results is in progress.

 

Teaching Experience (On-campus) 5

  1. 臨床腫瘍学入門

    2021

  2. 臨床腫瘍学入門

    2020

  3. 臨床腫瘍学入門

    2019

  4. 臨床腫瘍学入門

    2018

  5. 臨床腫瘍学入門

    2017